Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Q3 2022 Syndax Pharmaceuticals Inc Earnings Call Transcript

Nov 03, 2022 / 08:30PM GMT
Release Date Price: $22.33 (-2.45%)
Operator

Good day, everyone, and welcome to the Syndax Third Quarter 2022 Earnings Conference Call. Today's call is being recorded.

At this time, I'd like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals. Please go ahead.

Sharon Klahre
Syndax Pharmaceuticals, Inc. - VP of IR & Communications

Great. Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's third quarter 2022 financial and operating results. I'm Sharon Klahre, and with me today to provide you an update on the company's progress and to discuss financial results are Michael Metzger, Chief Executive Officer; Dr. Briggs Morrison, President and Head of R&D; and Keith Goldan, Chief Financial Officer. Also joining us on the call for the question-and-answer session is Dr. Peter Ordentlich, Chief Scientific Officer; and Dr. Anjali Ganguli, Chief Business Officer.

This call is accompanied by a slide deck that has been posted on the Investors page of the company's website. You can now turn to our forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot